secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001558370-24-007951
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Q1 net loss $11.3M; IND cleared for VY-TAU01; cash $400M to 2027
------------------------------------------------------------------------

- Net loss of $11.3M vs net income of $124.0M in Q1 2023; collaboration revenue $19.5M down from $150.5M.
- Cash, equivalents and marketable securities of $400.5M as of March 31, 2024; runway into 2027.
- IND clearance from FDA for anti-tau antibody VY-TAU01 for Alzheimer's disease; Phase 1a dosing imminent.
- Development candidates selected in GBA1 and Friedreich's Ataxia gene therapy programs with Neurocrine; $8M total milestones triggered.
- Appointed Toby Ferguson, M.D., Ph.D., as Chief Medical Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000155837024007951/0001558370-24-007951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000155837024007951/vygr-20240513x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer